Latest filing published 30 Nov 2007 for Molecular Insight Pharmaceuticals, Inc., €13k.
Insider track record
No signal scores available.
Daniel Frank: trading record in brief
Daniel Frank discloses dealings in Molecular Insight Pharmaceuticals, Inc. to SEC (Form 4). The record holds 4 filings, for trades running from 1 February 2007 to 28 November 2007.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
The latest filing, published on 30 November 2007, reports an option exercise of €13k in Molecular Insight Pharmaceuticals, Inc. Typically, a trade is published a median of 4 days after it takes place. US insiders must file a Form 4 within two business days of a trade. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Daniel Frank
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 4,167 shares@ US$4.80Common Stock, par value $.01 per shareSEC:0001005477-07-009936:0
- 54,367 sharesCommon Stock, par value $0.01 per shareSEC:0001005477-07-000659:1
- 12,626 sharesCommon Stock, par value $0.01 per shareSEC:0001005477-07-000659:2
- 72,120 sharesCommon Stock, par value $0.01 per shareSEC:0001005477-07-000659:0
4 of 4 declarations
